194032-34-3Relevant articles and documents
ROCK KINASE INHIBITORS
-
Paragraph 0236-0237; 0240-0242, (2020/05/29)
The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
Isoquinoline derivatives and drugs
-
, (2008/06/13)
PCT No. PCT/JP97/00240 Sec. 371 Date Jul. 29, 1998 Sec. 102(e) Date Jul. 29, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/28130 PCT Pub. Date Aug. 7, 1997The invention relates to a compound of the following general formula [I] or a medicinally acceptable salt thereof, or a solvate thereof, wherein R1 represents alkyl, alkenyl, alkynyl, alkoxy, hydroxy, cyano, or halogen; R2 represents hydrogen, hydroxy, or halogen; R3 represents hydrogen, alkyl, or amidino; Ring A represents a 5 to 11-membered cyclic amino group which may be substituted, which cyclic amino group may be bridged between two carbon atoms in optional positions. The compound of this invention is useful for the prevention or treatment of cerebral tissue impairment due to the vasospasm following cerebral hemorrhage.